miR-127-5p targets the 3'UTR of human β-F1-ATPase mRNA and inhibits its translation

IMW and IMR are the recipients of pre-doctoral fellowships from the Plan de Formación de Profesorado Universitario (AP2007-03035) from the Ministerio de Educación and JAE-CSIC, respectively. The work was supported by grants from the Ministerio de Educación y Ciencia (BFU2010- 18903), by the Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII and by Comunidad de Madrid (S2011/BMD-2402), Spain. The CBMSO receives an institutional grant from Fundación Ramón Arece

miR-127-5p targets the 3'UTR of human â-F1-ATPase mRNA and inhibits its translation

The mitochondrial H+ATP synthase is a bottleneck component in the provision of metabolic energy by oxidative phosphorylation. The expression of its catalytic subunit (β-F1-ATPase) is stringently controlled at post-transcriptional levels during oncogenesis, the cell cycle and in development. Here we show that miR-127-5p targets the 3 UTR of β F1-ATPase mRNA (β-mRNA) significantly reducing its translational efficiency without affecting β mRNA abundance. Despite the reduced expression of βF1-ATPase in most human carcinomas, we observed no expression of miR-127-5p in different human cancer cell lines, minimizing the potential role of miR-127-5p as a regulator of the bioenergetic activity of mitochondria in cancer. In contrast, miR 127-5p is highly over-expressed in the human fetal liver. Consistent with previous findings in the rat, the expression of β F1-ATPase in the human liver also seems to be controlled at post-transcriptional levels during development, what might suggest a role for miR-127-5p in controlling β mRNA translation and thus in de fining the bioenergetic activity of human liver mitochondria. Moreover, immunolocalization techniques and subcellular fractionation experiments using different antibodies against β F1-ATPase reveal that the ectopic expression of β F1-ATPase at the cell surface of the hepatocytes and HepG2 cells is negligible or stands for scrutinyMinisterio de Educación y Ciencia (BFU2010-18903); Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER); ISCIII and by Comunidad de Madrid (S2011/BMD-2402); Fundación Ramón ArecesPeer Reviewe